Vertex Pharmaceuticals IncorporatedVRTX
Price$522.81Intrinsic value$495.095% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $495.09median of 6 methods · middle span $396-$824based on filings through 30 Jun 2026
Market Price $522.81Price as of 30 Sep 2026
Margin of Safety -5.3%as of 30 Sep 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 8.1% (near-term consensus, capped) · years 2–5: 12.3%/yr (balance of the path).11.5% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 611.8%Yr 711.2%Yr 810.7%Yr 910.1%Yr 109.6%
12.3% → 9.6%
Years 11–20: glide to long-run rate
Per-year rates
Yr 118.9%Yr 128.2%Yr 137.6%Yr 146.9%Yr 156.3%Yr 165.6%Yr 175.0%Yr 184.3%Yr 193.7%Yr 203.0%
9.6% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)9.6%
Discount rate (cost of equity) 7.3%
Volatility vs market (adjusted beta)0.53

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetVertex Pharmaceuticals IncorporatedVRTXHealth Care
Valuation
P/E30.4×
P/S10.4×
P/B6.5×
EV / Revenue10.1×
EV / EBITDA—
Profitability
Gross margin8,624.0%
Operating margin3,810.0%
Net margin35.0%
FCF margin30.2%
Returns
ROE21.8%
ROA16.1%
ROIC27.3%
Growth
Revenue growth (YoY)14.2%
5-yr fwd EPS growth11.5%
Financial strength
Debt / Equity0.10×
Current ratio3.19×
Altman Z-Score13.1
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.